Celltrion Secures Global Rights to Autoimmune Drug Candidate from U.S. Biotech Kyigen
Published
Celltrion announced that it has secured exclusive global development and commercialization rights to the autoimmune disease drug candidate 'KG013' from U.S. biotech company Kyigen.
Autoimmune diseases are conditions in which the body's immune cells attack normal tissues. Through this agreement, Celltrion will be able to develop and sell the candidate exclusively worldwide.
The total value of the deal is up to $580.5 million. The contract amount includes payments that will be made depending on development milestones and sales performance. In the industry, acquiring drug candidates from external sources is seen as a way to help reduce drug development time and costs.
Celltrion has steadily expanded its business in the biopharmaceutical field. Through this agreement, the company is now able to prepare a new product line in the area of autoimmune disease treatments. However, drug candidates must undergo clinical trials and have their safety and efficacy confirmed before they can be approved as actual treatments.
Sources: IT타임스
More South Korea news
- Digital TVET master's program launches in South Korea
- Gyeongbuk health group donates 100 boxes of grapes to children
- US Big Tech Pursues Multi-Trillion Won Investments in South Korean Data Centers Amid Uncertainty
- KB Insurance to Hold Open Recruitment for New Employees in Second Half of 2026
- Kolmar Korea Wins CES Beauty Tech Best Innovation Award for Second Straight Year, Setting World First
- China Closes In on Korea's Core LNG Carrier Market, Expanding from Mega-Vessels to Equipment
- China's Rapid Technological Development: South Korea Must Change Its Regulations and Labor System
- Ambassador Michelle Steel: American Companies Operating in Korea Should Compete in a Fair Environment